For 2023, Boston Scientific is also targeting 50bps annual margin expansion and "strong" free cash flow. Comments made by CEO Michael Mahoney at the JPMorgan Healthcare Conference.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BSX: